Cossu Giulia, La Rosa Stefano, Brouland Jean Philippe, Pitteloud Nelly, Harel Ethan, Santoni Federico, Brunner Maxime, Daniel Roy Thomas, Messerer Mahmoud
Service of Neurosurgery, University Hospital of Lausanne, University of Lausanne, 1005 Lausanne, Switzerland.
Unit of Pathology, Department of Medicine and Technological Innovation, University of Insubria, 21100 Varese, Italy.
Cancers (Basel). 2023 Sep 8;15(18):4471. doi: 10.3390/cancers15184471.
About a third of Pituitary Neuroendocrine Tumors (PitNETs) may show aggressive behavior. Many efforts have been performed for identifying possible predictive factors to early determine the future behavior of PitNETs. Programmed cell death ligand 1 (PD-L1) expression was associated with a more aggressive biology in different solid tumors, but its role in PitNET is not well-established yet. Our study aims to analyze PD-L1 expression in a surgical cohort of PitNETs to determine its association with radiological invasion and pathology findings, as well as with long-term recurrence rates.
We performed a retrospective analysis in a series of 86 PitNETs. Clinical presentation and radiological features of the preoperative period were collected, as well as pathological data and follow-up data. The rate of PD-L1 expression was immunohistochemically evaluated and expressed as a tumor proportion score (TPS). We assessed its relationship with cavernous sinus invasion and Trouillas' classification as primary outcomes. Secondary outcomes included the TPS' relationship with histopathological markers of proliferation, hormonal expression, tumor size and long-term recurrence rates. We calculated the optimal cut-point for the primary outcomes while maximizing the product of the sensitivity and specificity and then we evaluated the significance of secondary outcomes with logistic regression analysis.
Eighty-six patients were included in the analysis; 50 cases were non-functional PitNETs. The TPS for PD-L1 showed a highly right-skewed distribution in our sample, as 30.2% of patients scored 0. Using Trouillas' classification, we found that "proliferative" cases have a significantly higher probability to express PD-L1 in more than 30% of tumor cells (OR: 5.78; CI 95%: 1.80-18.4). This same cut-point was also associated with p53 expression. A positive association was found between PD-L1 expression and GH expression ( = 0.001; OR: 5.44; CI 95%: 1.98-14.98), while an inverse relationship was found with FSH/LH expression ( = 0.014; OR = 0.27, CI 95%: 0.10-0.76). No association was found with CS invasion, tumor size, bone erosion or dura invasion. We could not find any association between PD-L1 expression and recurrence.
PD-L1 expression was associated with proliferative grades of Trouillas' classification and p53 expression. We also confirmed a higher expression of PD-L1 in somatotroph tumors. Larger studies are necessary to investigate the relationship between PD-L1 expression and aggressive behaviors.
约三分之一的垂体神经内分泌肿瘤(PitNETs)可能表现出侵袭性。人们已做出诸多努力来确定可能的预测因素,以便早期判断PitNETs的未来行为。程序性细胞死亡配体1(PD-L1)表达与不同实体瘤中更具侵袭性的生物学行为相关,但其在PitNET中的作用尚未明确。我们的研究旨在分析PitNETs手术队列中的PD-L1表达情况,以确定其与放射学侵袭、病理学结果以及长期复发率之间的关联。
我们对86例PitNETs进行了回顾性分析。收集了术前的临床表现和放射学特征,以及病理数据和随访数据。通过免疫组织化学评估PD-L1表达率,并以肿瘤比例评分(TPS)表示。我们评估了其与海绵窦侵袭和Trouillas分类的关系作为主要结果。次要结果包括TPS与增殖的组织病理学标志物、激素表达、肿瘤大小和长期复发率的关系。我们计算了主要结果的最佳切点,同时最大化敏感性和特异性的乘积,然后通过逻辑回归分析评估次要结果的意义。
86例患者纳入分析;50例为无功能PitNETs。在我们的样本中,PD-L1的TPS呈高度右偏分布,30.2%的患者评分为0。采用Trouillas分类法,我们发现“增殖性”病例在超过30%的肿瘤细胞中表达PD-L1的概率显著更高(比值比:5.78;95%置信区间:1.80 - 18.4)。相同的切点也与p53表达相关。PD-L1表达与生长激素(GH)表达之间存在正相关(P = 0.001;比值比:5.44;95%置信区间:1.98 - 14.98),而与促卵泡生成素/促黄体生成素(FSH/LH)表达呈负相关(P = 0.014;比值比 = 0.27,95%置信区间:0.10 - 0.76)。未发现与海绵窦侵袭、肿瘤大小、骨质侵蚀或硬脑膜侵袭相关。我们未发现PD-L1表达与复发之间存在任何关联。
PD-L1表达与Trouillas分类的增殖等级和p53表达相关。我们还证实了生长激素瘤中PD-L1表达较高。需要更大规模的研究来探讨PD-L1表达与侵袭性行为之间的关系。